• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home The Classics Gastroenterology Classics

Intravenous omeprazole after endoscopy reduces rebleeding in patients with peptic ulcers [Classics Series]

bys25qthea
December 6, 2013
in Gastroenterology Classics, The Classics
Reading Time: 2 mins read
Share on FacebookShare on TwitterShare on LinkedIn

Image: CC/L. academia

1. After endoscopic treatment, intravenous omeprazole significantly reduces the risk of rebleeding in patients with peptic ulcers at 3, 7, and 30 days

Original Date of Publication: August 3, 2000

Study Rundown: The findings of this trial demonstrate the value of a proton pump inhibitor in reducing the risk of rebleeding in patients with peptic ulcers. The fact that this study was carried out at a single centre in a predominantly Chinese population may limit the generalizability of the study. Moreover, the use of intravenous omeprazole is another concern, as it may not be available in certain other practice settings. Other studies, however, have demonstrated similar benefits with using orally administered proton pump inhibitors.

In sum, intravenous omeprazole reduces the risk of rebleeding in patients with bleeding peptic ulcers after endoscopic treatment.

Click to read study in NEJM

EvidencePulse™by 2 Minute Medicine®

How does Intravenous omeprazole after endoscopy reduces rebleeding in patients with peptic ulcers apply to your patient?

Describe your patient and EvidencePulse weighs this trial against later evidence and current guidelines, with citations.

Ask EvidencePulse

For a fuller review of the evidence, Deep research is a core feature of 2MM Max.

In-Depth [randomized controlled study]: This trial, published in 2000 in NEJM, sought to explore the value of intravenous omeprazole after endoscopy to reduce the risk of rebleeding in patients with peptic ulcers. After endoscopic treatment, bleeding peptic ulcers have been shown to rebleed in 15-20 percent of patients, though acid suppression may help stabilize clots and reduce the bleeding risk.

The trial was conducted at the Chinese University of Hong Kong. A total of 240 patients were randomized to receive either intravenous omeprazole (i.e., 80 mg bolus, then 8 mg/hour for 72 hours) or placebo after endoscopic treatment for bleeding peptic ulcers. Treatment with omeprazole significantly reduced the risk of recurrent bleeding at days 3, 7, and 30 compared to placebo. Moreover, omeprazole significantly reduced the length of hospitalization and blood transfusion requirements, though there were no significant differences in mortality between the two groups.

By Adrienne Cheung, Andrew Cheung, M.D.

Trials since this one

What later trials found on the same question.

  1. 2006

    Ceftriaxone vs. norfloxacin for prophylaxis in patients with cirrhosis and gastrointestinal bleeding In The Classics

    In cirrhotic patients who presented with gastrointestinal bleeding, patients treated with ceftriaxone were significantly less likely to develop proved or possible infections when compared to those treated with…

  2. 2007

    Omeprazole before endoscopy in patients with gastrointestinal bleeding In The Classics

    Compared to placebo, treating patients with omeprazole bolus and infusion prior to endoscopy significantly reduces the need for endoscopic therapy, the rate of post-endoscopy active bleeding, and shortens hospital stays.

3 more since 2000

2MM+ See every trial since Intravenous omeprazole after endoscopy reduces rebleeding in patients with peptic ulcers

2MM+ shows the full timeline of later trials on this question, with what each one found, and lets you save trials to reading lists for rounds, journal club and boards.

See 2MM+ plans Sign in

Citation: Lau JY, Sung JJ, Lee KK, Yung MY, Wong SK, Wu JC, et al. Effect of intravenous omeprazole on recurrent bleeding after endoscopic treatment of bleeding peptic ulcers. N Engl J Med. 2000 Aug 3;343(5):310-6. doi: 10.1056/nejm200008033430501. PMID: 10922420.

© 2013 2 Minute Medicine, Inc. All rights reserved. No part of this article may be reproduced, distributed or transmitted in any form or by any means without the prior written permission of 2 Minute Medicine, Inc. To license this content, contact 2 Minute Medicine, Inc. This article is for informational and educational purposes only; it is not medical advice and does not replace the judgment of a qualified healthcare professional.
Image: © 2 Minute Medicine

Tags: endoscopyomeprazolepeptic ulcers

New landmark trials, every weekday

The free 2 Minute Medicine Daily Brief: practice-changing studies summarized by physicians, in your inbox.

Your subscription opens securely in a new tab.

More Gastroenterology and hepatology Classics

Previous Post

Chlorhexidine bathing significantly reduces the development of hospital-acquired blood-stream infections

Next Post

Study hints at causal link between lipoprotein(a) and calcific aortic stenosis

Next Post

Study hints at causal link between lipoprotein(a) and calcific aortic stenosis

Surgical crisis checklists improve performance during operating-room crisis simulations

Ethical argument for opt-out approach to DNR status in terminally ill children

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

NPI Lookup · Free

Look up any US clinician

Search by name or NPI number, live from the CMS NPI Registry.

  • OIG exclusion check
  • Licenses and specialties
  • No account needed
Open NPI Lookup →

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • In topline phase 3 results, nomelcitinib improved PASI 90 and PGA 0/1 responses versus placebo in plaque psoriasis
  • Intraosseous cefuroxime (Ceftin) may improve tissue delivery compared to intravenous administration during total knee arthroplasty
  • 2 Minute Medicine Rewind November 2, 2026
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ physician-written reports
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓NPI watchlist + bulk NPI verification

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • ICD-10 Code Lookup
    • Medical School Rankings
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.